Ironwood Pharmaceuticals, Inc.
Price Action
Technical Summary
EMERGING TRENDIronwood Pharmaceuticals, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 96), indicating clear outperformance against the broad market. Earnings contraction of 191% provides fundamental context to the price action. However, price is extended 30% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.17 | +15.71% | ABOVE |
| 50 SMA | $3.72 | +29.67% | ABOVE |
| 100 SMA | $3.98 | +21.23% | ABOVE |
| 150 SMA | $3.45 | +39.96% | ABOVE |
| 200 SMA | $2.87 | +68.47% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is IRWD in an uptrend right now?
IRWD has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is IRWD overbought or oversold?
IRWD's RSI (14) is 66. The stock is in neutral territory, neither overbought nor oversold.
Is IRWD outperforming the market?
IRWD has a Relative Strength (RS) Rating of 96 out of 99. Yes, IRWD is a market leader, outperforming 96% of all stocks over the past 12 months.
Where is IRWD in its 52-week range?
IRWD is trading at $4.83, which is 84% of its 52-week high ($5.78) and 82% above its 52-week low ($0.53).
How volatile is IRWD?
IRWD has a Beta of 2.50 and 52-week volatility of 111%. It's more volatile than the S&P 500 - expect bigger swings.